Wincap Financial LLC Sells 4,453 Shares of CVS Health Corporation $CVS

Wincap Financial LLC decreased its stake in CVS Health Corporation (NYSE:CVS) by 18.6% during the second quarter, Holdings Channel.com reports. The institutional investor owned 19,480 shares of the pharmacy operator’s stock after selling 4,453 shares during the quarter. CVS Health accounts for about 1.1% of Wincap Financial LLC’s portfolio, making the stock its 24th largest position. Wincap Financial LLC’s holdings in CVS Health were worth $1,344,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its stake in shares of CVS Health by 87.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock valued at $672,598,000 after purchasing an additional 4,632,530 shares in the last quarter. Dodge & Cox boosted its stake in shares of CVS Health by 4.8% in the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after purchasing an additional 3,353,223 shares in the last quarter. Nuveen LLC purchased a new stake in shares of CVS Health in the 1st quarter valued at $204,421,000. Invesco Ltd. boosted its stake in shares of CVS Health by 13.2% in the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after purchasing an additional 2,375,764 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of CVS Health by 815.2% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock valued at $183,701,000 after purchasing an additional 2,372,121 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 0.6%

Shares of CVS opened at $82.44 on Tuesday. The stock has a market capitalization of $104.56 billion, a P/E ratio of 23.03, a PEG ratio of 0.90 and a beta of 0.60. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.74. The firm has a fifty day simple moving average of $75.82 and a two-hundred day simple moving average of $68.75. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $83.52.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The business had revenue of $98.92 billion during the quarter, compared to analyst estimates of $94.87 billion. During the same period in the prior year, the business earned $1.83 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a $0.665 dividend. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.2%. CVS Health’s dividend payout ratio is 74.30%.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares in the company, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on CVS shares. Bernstein Bank cut their price objective on shares of CVS Health from $78.00 to $72.00 and set a “market perform” rating for the company in a research note on Wednesday, July 16th. Barclays upped their price objective on shares of CVS Health from $80.00 to $87.00 and gave the company an “overweight” rating in a research note on Thursday, September 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of CVS Health in a research note on Tuesday, August 26th. Mizuho increased their price target on shares of CVS Health from $76.00 to $88.00 and gave the company an “outperform” rating in a research report on Thursday, October 9th. Finally, Robert W. Baird raised shares of CVS Health from a “neutral” rating to an “outperform” rating and increased their price target for the company from $71.00 to $82.00 in a research report on Thursday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $83.38.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.